Annual Drug Patent Expirations for ATRIPLA
Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for ATRIPLA.
This drug has one hundred and fourteen patent family members in thirty-one countries.
The generic ingredient in ATRIPLA is efavirenz; emtricitabine; tenofovir disoproxil fumarate. Two suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com